Chapter 54: Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease

1993 ◽  
pp. 439-445 ◽  
Author(s):  
Robert Davis ◽  
Charlotte Raby ◽  
Michael J. Callahan ◽  
William Lipinski ◽  
Roy Schwarz ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Therapeutic Agents ◽  
Muscarinic Agonists ◽  
Subtype Selective

scholarly journals Platinum-based inhibitors of amyloid-  as therapeutic agents for Alzheimer's disease

2008 ◽  
Vol 105 (19) ◽  
pp. 6813-6818 ◽  
Author(s):  
K. J. Barnham ◽  
V. B. Kenche ◽  
G. D. Ciccotosto ◽  
D. P. Smith ◽  
D. J. Tew ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Therapeutic Agents

scholarly journals Progress Report on the Canadian Multicentre Trial of Tetrahydroaminoacridine with Lecithin in Alzheimer's Disease

1989 ◽  
Vol 16 (S4) ◽  
pp. 543-546 ◽  
Author(s):  
S. Gauthier ◽  
R. Bouchard ◽  
Y. Bacher ◽  
P. Bailey ◽  
H. Bergman ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Rating Scale ◽  
Fixed Dose ◽  
Symptomatic Therapy ◽  
Muscarinic Agonists ◽  
Double Blind ◽  
Disability Rating Scale ◽  
Functional Autonomy ◽  
Disability Rating

ABSTRACT:Since the discovery of a significant depletion of acetylcholine in discrete areas of the brain of patients affected by Alzheimer's disease, attempts at symptomatic therapy have concentrated on acetylcholine supplementation, an approach that is based upon the efficacy of dopaminergic supplementation therapy for Parkinson's disease. Choline, then lecithin, used orally, failed to improve symptoms but the hypothesis that long-term choline supplementation might stabilize the course of Alzheimer's disease remains to be tested. Nerve growth factor may also offer that possibility. Bethanechol administered intracerebroventricularly did not help when a fixed dose was used but individual titration of more selective muscarinic agonists may prove more effective. In this article we report that tetrahydroaminoacridine (THA), given together with highly concentrated lecithin, appears to bring improvement in cognition and in functional autonomy using the Mini Mental State and the Rapid Disability Rating Scale-2 respectively, without change in behavior as reflected by the Behave-AD. Double-blind cross-over studies are in progress to establish its efficacy. Improvement in study design and means of assessment of cognition, functional autonomy and behavior have been made possible by these drug trials.

scholarly journals Multi-target-directed phenol–triazole ligands as therapeutic agents for Alzheimer's disease

2017 ◽  
Vol 8 (8) ◽  
pp. 5636-5643 ◽  
Author(s):  
Michael R. Jones ◽  
Emilie Mathieu ◽  
Christine Dyrager ◽  
Simon Faissner ◽  
Zavier Vaillancourt ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Therapeutic Agents ◽  
Peptide Aggregation ◽  
Primary Neurons ◽  
Aβ Peptide

A series of multi-target-directed ligands are described that bind Cu, act as antioxidants, modulate Aβ peptide aggregation, and abolish Aβ toxicity in primary neurons.

The olfactory system in Alzheimer’s disease: Pathology, pathophysiology and pathway for therapy

2013 ◽  
Vol 4 (1) ◽  
Author(s):  
Tibor Kovács
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Side Effects ◽  
Olfactory System ◽  
Therapeutic Agents ◽  
Non Invasive ◽  
Degenerative Disorders ◽  
Invasive Method

AbstractOlfaction is frequently mentioned as a “neglected sense”, although the olfactory system has several interesting and unique anatomical and physiological features. Olfactory involvement is present in several degenerative disorders, especially in Alzheimer’s disease (AD). The peripheral and central parts of the olfactory system are damaged even in the early stages of AD, manifesting in profound olfactory deficits. Besides the early pathology, the olfactory system may be involved in the pathogenesis of AD by providing a route of entry for pathological agents still unknown. In contrast to this olfactory vector hypothesis, the olfactory system can be used to deliver therapeutic agents in AD, such as nerve growth factor and insulin, by decreasing the side-effects of the therapy or providing a non-invasive method of delivery.

Sign in / Sign up

Export Citation Format

Share Document